MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$19,510,296
Net loss
-$17,785,071
Accrual of paid-in-kind
dividends on series a...
$1,725,225
Grant income
$139,835
Change in fair value of
contingent consideration
-$116,000
Interest income
$91,888
Loss before income
taxes
-$17,553,762
Deferred income tax
provision
$231,309
Total other income
(expense)
$201,267
Change in fair value of
warrant liabilities
$125,348
Currency exchange loss
(gain)
-$21,108
Operating loss
-$17,755,029
Total operating
expenses
$17,755,029
Acquired in-process
research and development...
$10,426,257
Research and development
$5,106,949
General and
administrative
$2,221,823
Back
Back
Income Statement
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)
source: myfinsight.com